>98% by SDS-PAGE analyses. >90% by RP-HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by the stimulation of protein synthesis using rat L6 myoblasts is less than 10ng/ml, corresponding to a specific activity of >1.0×105IU/mg.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in 20mM PB, pH7.2.
Endotoxin
Less than 0.01EU/μg of rHuLR3 IGF-1 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
IGF-1 belonged to the insulin gene family, is a mitogenic polypeptide growth factor that stimulate the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. It is produced primarily by the liver as an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion. The production of IGF-1 is stimulated by growth hormone (GH) and can be retarded by undernutrition, growth hormone insensitivity, lack of growth hormone receptors, or failures of the downstream signaling pathway post GH receptor including SHP2 and STAT5B. The LR3 IGF-1 is a long-term analog of human IGF-1, specifically designed and manufactured for mammalian cell culture to support large-scale manufacturing of recombinant biopharmaceuticals. Manufactured using all Animal-Free reagents.
>98% by SDS-PAGE analyses. >90% by RP-HPLC analyses.
Biological Activity
Fully biologically active when compared to standard. The ED50 as determined by the stimulation of protein synthesis using rat L6 myoblasts is less than 10ng/ml, corresponding to a specific activity of >1.0×105IU/mg.
Physical Appearance
Sterile Filtered White lyophilized (freeze-dried) powder.
Formulation
Lyophilized from a 0.2μm filtered concentrated solution in 20mM PB, pH7.2.
Endotoxin
Less than 0.01EU/μg of rHuLR3 IGF-1 as determined by LAL method.
Reconstitution
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤-20℃. Further dilutions should be made in appropriate buffered solutions.
Category
Cytokine
Background
IGF-1 belonged to the insulin gene family, is a mitogenic polypeptide growth factor that stimulate the proliferation and survival of various cell types including muscle, bone, and cartilage tissue in vitro. It is produced primarily by the liver as an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion. The production of IGF-1 is stimulated by growth hormone (GH) and can be retarded by undernutrition, growth hormone insensitivity, lack of growth hormone receptors, or failures of the downstream signaling pathway post GH receptor including SHP2 and STAT5B. The LR3 IGF-1 is a long-term analog of human IGF-1, specifically designed and manufactured for mammalian cell culture to support large-scale manufacturing of recombinant biopharmaceuticals. Manufactured using all Animal-Free reagents.
